Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany

News Releases

Award for our company: Best employer
Award for our company: Best employer
Our company is one of the world’s best employers. This has now been officially verified with the Global Top Employer 2017 certificate. This award acknowledges that we provide exceptional employee conditions, nurture and develop talented people, and always strive to optimize our employment relationships.
 
FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Urothelial Carcinoma for Priority Review
FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Urothelial Carcinoma for Priority Review
Merck KGaA, Darmstadt, Germany, and Pfizer Inc. today announced that the US Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for avelumab*, as a treatment for patients with locally advanced or metastatic urothelial carcinoma (mUC) with disease progression on or after platinum-based therapy. The BLA was submitted by EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the US and Canada. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of August 27, 2017, for avelumab in this indication.
 
Access Accelerated – joint initiative to fight non-communicable diseases
Access Accelerated – joint initiative to fight non-communicable diseases
At the World Economic Forum in Davos, Switzerland, 22 leading global pharma companies, including Merck KGaA, Darmstadt, Germany, announced plans to launch a worldwide initiative called Access Accelerated. The initiative aims to improve the prevention and treatment of non-communicable diseases (NCDs) in low- and middle-income countries. NCDs include, for example, cancer, diabetes, cardiovascular and chronic respiratory diseases.
 
Please contact media.relations@emdgroup.com for news releases published before 2014.
 
 
 
 
 
 
 
 
 
 
 

DISCLAIMER

Publication of Merck KGaA, Darmstadt, Germany.
There are two different, unaffiliated companies that use the name MERCK. Merck KGaA, Darmstadt, Germany, which operates this website, uses the firm name “Merck KGaA, Darmstadt, Germany,” in the United States and Canada, and also uses “EMD Serono” in biopharma, “MilliporeSigma” in life science and “EMD Performance Materials” in materials business. The other company, Merck & Co., Inc. holds the rights in the trademark MERCK in the United States and Canada. Merck & Co. is not affiliated with or related to Merck KGaA, Darmstadt, Germany, which owns the MERCK trademark in all other countries of the world.   To reflect such fact and to avoid any confusion, certain logos, terms and business descriptions of the publications on this website have been substituted or modified, such as by referring to “Merck KGaA, Darmstadt, Germany” instead of “Merck” standing alone.  Publications on this webpage, therefore, slightly deviate from the otherwise identical versions accessible outside the United States and Canada.
 

FOR MEDIA INQUIRIES, CONTACT

Media Team
POSTAL ADDRESS 
Merck KGaA, Darmstadt, Germany
Frankfurter Straße 250 
64293 Darmstadt 
Germany
Tel.: +49 6151 72-5000
Fax: +49 6151 72-3138
 
Merck KGaA, Darmstadt, Germany on Facebook
Twitter